抗肿瘤药达沙替尼新的合成工艺研究
出处
《中国伤残医学》
2010年第5期86-87,共2页
Chinese Journal of Trauma and Disability Medicine
参考文献7
-
1Dasatinib[J].Drugs of the future.2006,31(4):291-303.
-
2Louis J.Lombardo,Francis Y.Lee,et al.Discovery of N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl) piperazin-1-yl)-2-methyl pyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825),a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays[J].J.Med.Chem.2004,47:6658-6661.
-
3Jagabandhu Das,Ramesh Padmanabha,et al.Cyclic protein tyrosine kinase inhibitors[P].US:6596746,2003-7-22.
-
4Bang-Chi Chen,Roberto Droghini,et al.Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors[P].US:2006/0004067,2006-1-5.
-
5Jagabandhu Das,Ping Chen,et al.2-Aminothiazole as a Novel Kinase Inhibitor Template.Structure-Activity Relationship Studies toward the Discovery of N-(2-Chloro-6-methylphenyl)-2[[6-[4-(2-hydroxyethyl)-1-piperazinyl)] -2-methyl-4-pyrimidinyl] amino)] -1,3-thiazole-5-carboxamide (Dasatinib,BMS-354825),as a Potent pan-Src Kinase Inhibitor[J].J.Med.Chem.2006,49:6819-6832.
-
6Herman Eldridge Faith.Production of methyl formylchloroacetate[P].US:2405820,1946-8-13.
-
7藏佳良 陈一芬 冀亚飞.达沙替尼的合成.中国医药工业杂志,2008,11.
-
1张少宁,魏红涛,吉民.达沙替尼的合成[J].中国医药工业杂志,2010,41(3):161-163. 被引量：12
-
2美国FDA批准百时美施贵宝的白血病药物Sprycel[J].中华医学信息导报,2006,21(15):17-17.
-
3黄睿,何小兵,陈中豪,熊远珍.达沙替尼的合成研究[J].化学与生物工程,2013,30(10):48-50.
-
4臧佳良,陈一芬,冀亚飞.达沙替尼的合成[J].中国医药工业杂志,2009,40(5):321-323. 被引量：10
-
5要闻速递[J].世界临床药物,2007,28(1):3-4.
-
6张振华（摘）.Dasatinib治疗耐imatinib CML的初期效果良好[J].国外药讯,2006(7):25-26.
-
7刘敏（摘）.04019 06年12月欧洲批准和上市的新产品[J].国外药讯,2007(4):10-12.
-
8美国FDA发布关于白血病治疗药物Sprycel的风险警告[J].中国新药杂志,2012,21(2):108-108.
-
9通用名药与药物经济学——日本NIH药价目录增加11个NCE[J].国外药讯,2009(5):34-35.
-
10袁霞,陈晓光.新型Bcr／Abl和Src双靶点抑制剂FB2治疗伊马替尼耐药的慢性髓系白血病的作用及机理研究[J].中国药理通讯,2009,26(2):20-20.
;
